Recombinant Human IL-36 beta/IL-1F8 Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human IL-36 beta/IL-1F8 Protein, CF Summary

• Additional Information: A New rh IL-36b is Now Available! The new truncated protein is 40-fold more active!
• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized recombinant human IL-36 beta at 1 µg/mL (100 µL/well) can bind recombinant human IL-1 Rrp2 Fc Chimera (Catalog # 872-RP) with a linear range of 0.15-5 µg/mL.
• Source: E. coli-derived human IL-36 beta/IL-1F8 protein
  Met1-Glu157
• Accession #: Q3MIH0
• N-terminal Sequence: Met1
• Protein/Peptide Type: Recombinant Proteins
• Gene: IL36B
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 17.7 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-36 beta/IL-1F8 Protein, CF

• family of interleukin 1-eta
• FIL1 eta
• FIL1
• FIL1-(ETA)
• FIL1H
• FILI-(ETA)
• IL-1 eta
• IL1-ETA
• IL1F8 (Canonical product IL-1F8a)
• IL-1F8 (FIL1-eta)
• IL1F8
• IL-1F8
• IL1H2
• IL-1H2
• IL36 beta
• IL-36 beta
• IL36B
• interleukin 1 family, member 8 (eta)
• interleukin 1, eta
• Interleukin 36, Beta
• Interleukin-1 eta
• interleukin-1 family member 8
• Interleukin-1 homolog 2
• Interleukin-1 Superfamily e
• Interleukin-36 Beta

Background

Human interleukin‑36 beta [IL‑36 beta ; previously IL‑1F8 and also named FIL‑1 eta  (eta) and IL‑1H2] is a member of the IL‑1 family of proteins (1 ‑ 3, 6). IL‑1 family members include IL‑1 beta , IL‑1 alpha , IL‑1ra, IL‑18, IL‑36Ra/IL‑1F5, IL‑36 alpha /IL‑1F6, IL‑37/IL‑1F7, IL‑36 gamma /IL‑1F9 and IL‑1F10 (4, 6). All family members show a 12 beta ‑stranded beta ‑trefoil configuration, and are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C‑terminal 70 amino acid (aa) residues have been reported (3). IL‑36 beta /IL‑1F8 isoform 2 is synthesized as a 157 aa protein that contains no signal sequence and no prosegment (1 ‑ 2). Unlike IL‑36 beta /IL‑1F8 isoform 1 which lacks potential N‑linked glycosylation sites, isoform 2 contains one potential N‑linked glycosylation site in its unique C‑terminus. IL‑36 beta /IL‑1F8 is reported to be actively secreted (1). Human IL‑36 beta /IL‑1F8 isoform 2 shares 61% aa identity with mouse IL‑1 ra, a 183 aa form of IL‑36 beta /IL‑1F8. Within the IL‑1 family, IL‑36 beta /IL‑1F8 shares 30%, 32%, 37%, 46%, 34%, 45% and 28% aa sequence identity with IL‑1 ra, IL‑1 beta , IL‑36Ra/IL‑1F5, IL‑36 alpha /IL‑1F6, IL‑37/IL‑1F7, IL‑36 gamma /IL‑1F9 and IL‑1F10, respectively. Cells reported to express IL‑36 beta /IL‑1F8 include resting and activated monocytes and B cells (1, 4). The receptor for IL‑36 beta /IL‑1F8 is reported to be a combination of IL‑1 Rrp2 and IL‑1 RAcP (5). Recombinant IL‑36 beta /IL‑1F8, along with IL‑36 alpha /IL‑1F6 and IL‑36 gamma /IL‑1F9, has been shown to activate the pathway involving NF‑ kappa B and MAPK in an IL‑1 Rrp2 dependent manner.

1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
2. Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
3. Nicklin, M.J.H. et al. (2002) Genomics 79:718.
4. Dunn, E. et al. (2001) Trends Immunol. 22:533.
5. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
6. Dinarello, C. et al. (2010) Nat. Immunol. 11:973.

Publications for IL-36 beta/IL-1F8 (1099-IL/CF)(3)

Publications using 1099-IL/CF

• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)
• Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O'Toole M, Young DA, Fouser LA, Nickerson-Nutter C, Collins M, Dunussi-Joannopoulos K, Medley QG Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol., 2011-09-01;131(12):2428-37. 2011-09-01 [PMID: 21881584] (Bioassay, Human)
• Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, Bas S, Duffy T, Noger M, Guerne PA, Nicklin MJ, Gabay C The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res. Ther., 2006-04-28;8(3):R80. 2006-04-28 [PMID: 16646978] (ELISA (Standard))

Bioinformatics

• Gene Symbol: IL36B
• Uniprot:
  • Q3MIH0()